Health Scope

Published by: Kowsar

Bone Mineral Density (BMD) and Chemical Biomarkers Among Patients with Thalassemia Major and Intermedia in Iran

Ali Reza Ansari-Moghadam 1 , Hossein Adineh 2 , * , Iraj Zareban 3 , Zeinab Almasy 4 and Mahtab Maghsudlu 5
Authors Information
1 Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Epidemiology and Biostatistics, Iranshahr University of Medical Sciences, Iranshahr, Iran
3 Health Education Department, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
4 Department of Epidemiology and Biostatistics, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
5 Department of Thalassemia, Transfusion Research Center Tehran, Iran
Article information
  • Health Scope: November 2018, 7 (4); e64137
  • Published Online: October 21, 2018
  • Article Type: Research Article
  • Received: November 17, 2017
  • Revised: March 20, 2018
  • Accepted: April 15, 2018
  • DOI: 10.5812/jhealthscope.64137

To Cite: Ansari-Moghadam A R, Adineh H, Zareban I, Almasy Z, Maghsudlu M. Bone Mineral Density (BMD) and Chemical Biomarkers Among Patients with Thalassemia Major and Intermedia in Iran, Health Scope. 2018 ; 7(4):e64137. doi: 10.5812/jhealthscope.64137.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Muncie HJ, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009;80(4):339-44. [PubMed: 19678601].
  • 2. Haddad A, Tyan P, Radwan A, Mallat N, Taher A. Beta-thalassemia intermedia: A bird's-eye view. Turk J Haematol. 2014;31(1):5-16. doi: 10.4274/Tjh.2014.0032. [PubMed: 24764724]. [PubMed Central: PMC3996637].
  • 3. Valizadeh N, Farrokhi F, Alinejad V, Said Mardani S, Valizadeh N, Hejazi S, et al. Bone density in transfusion dependent thalassemia patients in Urmia, Iran. Iran J Ped Hematol Oncol. 2014;4(2):68-71. [PubMed: 25002928]. [PubMed Central: PMC4083203].
  • 4. Izadyar S, Fazeli M, Izadyar M, Salamati P, Gholamrezanezhad A. Bone mineral density in adult patients with major thalassaemia: Our experience and a brief review of the literature. Endokrynol Pol. 2012;63(4):264-9. [PubMed: 22933161].
  • 5. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassaemia. Nicosia (CY): Nicosia Thalassaemia International Federation; 2008.
  • 6. Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in beta-thalassemia syndromes. Spine (Phila Pa 1976). 2012;37(4):334-9. doi: 10.1097/BRS.0b013e31821bd095. [PubMed: 21494197].
  • 7. Akbarian M, Davatchi F, Salimzadeh A, Shahram F, Gharibdoust F, Nadji A, et al. Bone mass density in the normal population of Iran. Int J Rheum Dis. 2005;8(3):177-83. doi: 10.1111/j.1479-8077.2005.00154.x.
  • 8. Hare Yiğitoğlu P, Güzel R. Osteoporosis in thalassemia major. Turk J Osteoporos. 2012;18(3):89-91.
  • 9. Kosaryan M, Zadeh MF, Shahi VK. The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help? Pediatr Endocrinol Rev. 2004;2 Suppl 2:303-6. [PubMed: 16462716].
  • 10. Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev. 2008;6 Suppl 1:86-93. [PubMed: 19337161].
  • 11. Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev. 2008;6 Suppl 1:116-22. [PubMed: 19337164].
  • 12. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pakbaz Z, Tabatabaie SM, Bouzari N, et al. Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major. Pediatr Hematol Oncol. 2007;24(7):469-79. doi: 10.1080/08880010701533702. [PubMed: 17786783].
  • 13. Nakhakes C, Jaruluxananan S, Saengsuda Y, Saengsuda S. Risk factors for osteoporosis and the relationship between osteoporosis and hemoglobin level in adult patients with thalassemia in Rajavithi hospital. Asian Biomed. 2017;9(2):169-74. doi: 10.5372/1905-7415.0902.383.
  • 14. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010;14(2):182-92. doi: 10.1111/j.1542-4758.2009.00430.x. [PubMed: 20345388]. [PubMed Central: PMC5509753].
  • 15. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: An overview. J Osteoporos. 2010;2010:537673. doi: 10.4061/2010/537673. [PubMed: 20976089]. [PubMed Central: PMC2957233].
  • 16. Filosa A, Di Maio S, Aloj G, Acampora C. Longitudinal study on thyroid function in patients with thalassemia major. J Pediatr Endocrinol Metab. 2006;19(12):1397-404. doi: 10.1515/JPEM.2006.19.12.1397. [PubMed: 17252692].
  • 17. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, et al. Bone disease in thalassemia: A frequent and still unresolved problem. J Bone Miner Res. 2009;24(3):543-57. doi: 10.1359/jbmr.080505. [PubMed: 18505376]. [PubMed Central: PMC3276604].
  • 18. Larijani B, Hossein-Nezhad A, Mojtahedi A, Pajouhi M, Bastanhagh MH, Soltani A, et al. Normative data of bone Mineral Density in healthy population of Tehran, Iran: A cross sectional study. BMC Musculoskelet Disord. 2005;6:38. doi: 10.1186/1471-2474-6-38. [PubMed: 15992408]. [PubMed Central: PMC1180448].
  • 19. Hashemieh M, Azarkeivan A, Radfar M, Saneifard H, Hosseini-Zijoud SM, Noghabaei G, et al. Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran. Iran J Blood Cancer. 2014;6(3):143-8.
  • 20. Rafsanjani KA, Mafi N, Tafreshi RI. Complications of beta-thalassemia intermedia in Iran during 1996-2010 (single-center study). Pediatr Hematol Oncol. 2011;28(6):497-508. doi: 10.3109/08880018.2011.572144. [PubMed: 21728720].
  • 21. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: Epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233-8. doi: 10.1097/MPH.0b013e3180437e02. [PubMed: 17414565].
  • 22. Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr. 2007;44(1):29-32. [PubMed: 17277428].
  • 23. Aslan I, Canatan D, Balta N, Kacar G, Dorak C, Ozsancak A, et al. Bone mineral density in thalassemia major patients from antalya, Turkey. Int J Endocrinol. 2012;2012:573298. doi: 10.1155/2012/573298. [PubMed: 22778734]. [PubMed Central: PMC3388304].
  • 24. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z. Prevalence of osteoporosis in Iran: A meta-analysis. J Res Med Sci. 2013;18(9):759-66. [PubMed: 24381618]. [PubMed Central: PMC3872583].
  • 25. Kosaryan M, Vahidshahi K, Jamali AE, Sarparast L. [Bone mineral density (BMD) of patients with beta thalassemia]. J Mazand Univ Med Sci. 2012;22(86):63-73. Persian.
  • 26. Origa R, Fiumana E, Gamberini MR, Armari S, Mottes M, Sangalli A, et al. Osteoporosis in beta-thalassemia: Clinical and genetic aspects. Ann N Y Acad Sci. 2005;1054:451-6. doi: 10.1196/annals.1345.051. [PubMed: 16339696].
  • 27. Vogiatzi MG, Autio KA, Schneider R, Giardina PJ. Low bone mass in prepubertal children with thalassemia major: Insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab. 2004;17(10):1415-21. doi: 10.1515/JPEM.2004.17.10.1415. [PubMed: 15526720].
  • 28. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000;111(3):902-7. doi: 10.1046/j.1365-2141.2000.02392.x. [PubMed: 11122154].
  • 29. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, et al. Metabolic and endocrinologic complications in beta-thalassemia major: A multicenter study in Tehran. BMC Endocr Disord. 2003;3(1):4. doi: 10.1186/1472-6823-3-4. [PubMed: 12914670]. [PubMed Central: PMC194672].
  • 30. Trivedi DJ, Sagare A. Assessment of iron overload in homozygous and heterozygous beta thalassemic children below 5 years of age. J Krishna Inst Med Sci. 2014;3(2):17-22.
  • 31. de Vernejoul MC, Girot R, Gueris J, Cancela L, Bang S, Bielakoff J, et al. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J Clin Endocrinol Metab. 1982;54(2):276-81. doi: 10.1210/jcem-54-2-276. [PubMed: 7054221].
  • 32. Flynn DM, Fairney A, Jackson D, Clayton BE. Hormonal changes in thalassaemia major. Arch Dis Child. 1976;51(11):828-36. doi: 10.1136/adc.51.11.828. [PubMed: 1008588]. [PubMed Central: PMC1546074].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments